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Gene Expression Studies 
Animals for qPCR experiments.  Male mice, 8 weeks old, strain C57Bl/6J-0664 were 
ordered from Jackson Labs and entrained to 12 hour light/dark cycle for at least 1 week 
prior to use.  Mice were housed in solid bottom cages and fed standard chow with water 
available ad libitum. All procedures used in this study were approved by, and in 
accordance with, the guidelines of the Pfizer Animal Care and Use Committee. Animal 
facilities are accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care, International.  Mice were dosed at ZT11, one hour before lights 
off, by subcutaneous injection, with 8 mice per treatment group.  PF-670462 (4-[3-
cyclohexyl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamine) was dissolved 
in 20% beta-cyclodextran sulfobutyl ether in water at a 10 ml/kg dose volume.  Mice 
were sacrificed at time noted via CO2 euthanasia. Hypothalami and cortex were micro 
dissected and immediately frozen on dry ice, then stored at -80C until processed.    
RNA extraction and qPCR.  RNA isolation was carried out using Macherey-Nagel 
NucleoSpin kit  (catalog number 740 790.4) using the NucleoVac96 Vacuum Manifold 
(catalog number 740 681) according to the manufacturer’s instructions.  Samples were 
homogenized in lysis buffer using a 3mm steel bead (Qiagen) in a Retsch MM300 shaker 
at 20 Hz for five minutes. Synthesis of cDNA was carried out with the Applied 
Biosystems High Capacity RNA to cDNA kit (#4387406) following manufacturers 
protocol using 9ul of RNA as eluted from NucleoSpin kit, with cDNA diluted to a final 
volume of 170ul with water.  Quantitative PCR was performed in a 10ul reaction 
containing 4.5 ul of cDNA, 0.5ul 20X Taqman assay mix, and 5ul Taqman Fast Universal 
PCR Master Mix (Applied Biosystems #4367848) in 384 well plates (Applied 
Biosystems) using the cycling conditions specified by the manufacturer on the Applied 
Biosystems (AB) 7900 instrument.  Taqman gene expression assays purchased from 
Applied Biosystems are detailed in Table S8. Relative quantity for each gene was 
calculated in Excel using raw Ct data exported from AB SDS 2.3 software. The DDCt 
method was employed as described by Livac and Schmittgen (1), utilizing actin as the 
reference gene, the lowest abundance sample acting as reference sample. The average 
relative quantity for each timepoint is graphed with errors bars representing SEM.  
 
Behavior Studies 
Animals. Adult male C57BL/6J mice were used for all experiments. After acclimating 
for 1 week, the mice were anesthetized with 2.5% isoflurane and prepped for surgical 
implantation of an indwelling telemeter unit. A midline incision through skin and muscle 
was made in the ventral abdominal region, and a sterile telemeter (TA10TA-F20; Data 
Sciences International, St. Paul, MN) was inserted into the peritoneal cavity. The muscle 
was closed with absorbable suture and the skin was closed with wound clips. The animals 
were given 5 mg/kg s.c. carprofen and were allowed to recover in a clean cage beneath a 
heating lamp. Once ambulatory, the animals were placed in their home cages, the cages 
were placed on matrixed receivers, and the telemeters were activated and tested on the 
data collection system (Dataquest Acquisition Software, Data Sciences International). 
Telemeters were programmed to record activity and temperature and the collected data 
were uploaded into Matlab-based (The Mathworks Inc., Natick, MA) analysis software 
(ClockLab; ActiMetrics, WilmetteWilmette, IL) containing algorithms to determine and 
predict activity onsets and associated circadian parameters. Each cage contained a 
running wheel to encourage activity and was housed within a light-tight isolation 
chamber (four cages per box; Plastic Design, Inc., North Chelmsford, MA) with constant 
ventilation. Lighting for each box was set at 250 to 300 lux, and the light cycle was 
controlled with a timer (ChronTrol, San Diego, CA). The timing of lights on and off in 
each box was also recorded and checked daily. The mice were kept in a 12:12 LD 
(light/dark cycle of 12 h each) for at least 2 weeks after recovery from transmitter 
implantation surgery before initiation of the study to ensure their sleep/wake cycles were 
entrained to the LD cycle.  
 Before dosing, baseline data were reviewed over a 7d period to ensure that animals met 
exclusion criteria. Animals were excluded if their baseline (daily period) was less than 
23.9h or greater than 24.1h. Animals were also excluded if the characteristics of their 
data were insufficient to allow for reliable determination of activity onsets. Treatment 
groups were randomized across isolation chambers such that each chamber contained 
animals from different treatment groups. In each experiment, animals were either shifted 
into DD (DD dosing) or maintained in LD (LD dosing) and all were treated at circadian 
time 11 (CT11), which was 1h before the lights would normally have been turned off 
with the indicated dose of PF-670462 for the indicated number of days.  After the last day 
of dosing, mice in LD were shifted into DD and circadian measures followed for an 
additional 7 days. Data were then downloaded and for the 1d or 3d dosing, phase shifts 
were calculated as the time difference in behavior onset between the predosing week and 
after dosing as analyzed by the Clocklab software. For chronic dosing, phase shifts were 
calculated as the daily additive shift in onset. One-way ANOVA with Tukey’s or 
Dunnett’s post-test were used to analyze phase shifts.  
 
Pharmacokinetic Characterization 
Distribution Profiles. A single dose (32mg/kg) of PF-00670462 was administered to 
male C57/Bl6 mice (n=2-3 per dose/time point) as a subcutaneous injection based on 
pretreatment body weight and a dosing volume of 10 mL/kg. Drug was prepared on the 
same day of study in a dosing vehicle composed of 5/5/90 DMSO:cremophor:0.9% 
saline.  For sample collection, mice were placed under isofluorane anesthesia at 0.5, 1, 2, 
4, and 8h post dose, blood samples were obtained by cardiac puncture and collected into 
EDTA-containing tubes, which were stored on wet ice until plasma isolation. 
Subsequently, CSF was acquired via cistern magna puncture, transferred to a 
polypropylene tube, and immediately frozen on dry ice.  The whole brain was extracted, 
rinsed of excess blood with ice-cold saline, placed into a tared vial, weighed, and frozen 
on dry ice. For bioanalytical sample preparation, plasma and CSF samples were used as 
is, whereas brain tissue samples were first homogenized in a 4-fold volume (w:v) of  60% 
isopropanol solution.  Individual standard curves were prepared in respective control 
matrices.  Samples (50uL) were processed using an acetonitrile-mediated matrix 
precipitation methodology followed by a liquid chromatography-tandem mass 
spectrometry assay.   
Target Occupancy. All procedures were carried out in accordance with Institutional 
Animal Care and Use Committee guidelines under Animal Usage Protocol No. 15933. 
Male C57BL/6J mice from Jackson Laboratories, 9-12 weeks of age, were housed on a 
12-hour light/dark cycle and given food and water ad libitum.  Animals were allowed to 
acclimate for 5 days after arrival and were always used within 10 days of 
arrival.  [3H]PF-05236216 was prepared by the Pfizer Radiochemical Synthesis Group in 
Groton, CT.  Studies were performed using lot 00703442-029-rvc001, 70.7 Ci/mmol, 
0.770  mCi/ml in ethanol.  The [3H]PF-05236216 dosing solution was prepared by 
diluting the appropriate amount of stock solution in 0.9% saline to achieve a 100 mCi/ml 
solution. The appropriate amount of PF-670462, lot PF-00670462-00-0009, was weighed 
to achieve the dosing concentration specified (mg/kg) and dissolved in 20% 
sulfobutylether b-cyclodextrin (SBE BCD). Mice received a 10 ml/kg subcutaneous (SC) 
injection of PF-670462 at 30 minutes prior to euthanasia.  They then received a 3 ml/kg 
intraorbital injection of [3H]PF-05236216 at 1 minute prior to euthanasia.  PF-05175333 
(100 mg/kg, SC) was used to determine the level of non-specific binding.  Note that all 
doses were corrected for salt content of the drug. Mice were euthanized by live 
decapitation 30 minutes after dosing and brains removed.  Hypothalami were rapidly 
dissected and homogenized for approximately 3 seconds each using a polytron at its 
highest setting (5-6) in 10 volumes (100 mg/ml) of ice-cold assay buffer (50 mM Tris, 2 
mM MgCl2, pH 7.4).  Two replicates (200 ml each) of the resulting homogenates were 
filtered using a vacuum manifold apparatus with 25 mm Whatman GF/B filters presoaked 
in 0.3% polyethyleneimine (PEI).  The filters were soaked overnight in 10 ml of Biosafe 
scintillation fluid. The samples were then counted on a liquid scintillation counter.  The 




Incorporation of PF-670462 into the model. We incorporated PF-670462 into a 
recently developed mathematical model of intracellular mammalian circadian clocks (2). 
PF-670462 binds CK1δ/ε and inhibits the phosphorylation of CK1δ/ε (Figure S2). The 
inhibition of phosphorylation reduced the degradation rate of PER1/2, nucleus 
translocation of PER1/2 and binding rate of PER1/2 and CRY1/2 in the model. We 
considered the concentration of PF-670462 in four compartments: in plasma, brain tissue, 
cytoplasm and nucleus (Figure S2 and Table S6). To describe the import into and export 
out of these four compartments, 6 parameters were added. Because PF-670462 is 
absorbed to plasma very fast (<0.5h) (Figure 4a), we assumed that dosing is directly 
applied to the plasma compartment for simplicity. The addition of a new compartment 
(e.g. skin) describing drug administration did not change the behavior of model (data not 
shown). We also considered a clearance rate for free CK1δ/ε in plasma. The binding and 
unbinding rates of PF-670462 to CK1δ/ε are also considered. Since CK1δ/ε can freely 
exit the nucleus of the cell in the original model (2), we allowed for the rate of nuclear 
export of CK1δ/ε to be different when it is bound to PF-670462. Finally, we needed to 
choose an initial concentration of free PF-670462 in plasma when a 32 mg/kg dose is 
administrated (higher or lower doses can be determined by appropriately scaling this 
value). In total, this adds 11 parameters to the model while other parameters of the 
original model were left unchanged (Table S5). 
Definition of concentration in the model. We followed a convention from the circadian 
modeling field whereby all concentrations are defined as number of molecules/Vr, where 
Vr is a reference volume (2-5). Here, we chose Vr to be the volume of distribution in the 
cell cytosol (Figure S2a) as has been done previously. To convert to concentrations in the 
standard form used in multi-compartment models would require knowledge of the actual 
volumes of distribution, which remain unknown in some compartments. It would also 
require knowledge of the fraction of the flux of free PF-670462 from brain to a single 
cell, the fraction of the flux from plasma that goes specifically to brain rather than other 
tissues, and measures of absolute concentrations of clock proteins in single cells, which 
are still lacking (2, 6, 7). For these reasons, concentrations are viewed as relative and not 
absolute. We scaled variables to match data presented in Figure 4a. 
 
Ordinary differential equations of the mathematical model. Equations that describe 
the dynamics of CK1 inhibitor (PF-670462) are added to the original model (2), which 
are highlighted in red. The parameters and variables are described in Table S5-7. The 
equations of the original model are adopted from the supplementary information in Kim 
and Forger (2012) (2). 
 



























MnNp'=trNp*GB- tmc*MnNp - umNp*MnNp 
McNp'=tmc*MnNp-umNp*McNp 
 




















5) Dynamics of Free PF-670462 
 pInh'==-(uinp+nlpin)*pInh+nepin*bInh 
 bInh'=(nlbin+nepin)*bInh+nlpin*pInh+nebin*Inh 
Inh'= nlbin*bInh-(nebin+nlin)*Inh+ nein*nInh+(-inbin*Inh 
*Sum[x[jj][kk][ll][0][0],{jj,0,6},{kk,0,2},{ll,1,3,2}]) +inubin*Sum[x[jj][kk][ll][0][0],{jj,0,6},{kk,0,2},{ll,4,5}] 
nInh'== Inh*nlin-(nein)* nInh-




CK1-CK1 inhibitor (PF-670462) 
[x[j][k][l][m][n]'=   
If[(l==1)&&(m==0)&&(n==0),-inbin*Inh*x[j][k][l][m][n]+ inubin*x[j][k][4][m][n],0]+  
If[(l==3)&&(m==0)&&(n==0),-inbin*Inh*x[j][k][l][m][n]+ inubin*x[j][k][5][m][n],0]+  
If[(l==4)&&(m==0)&&(n==0), inbin*Inh*x[j][k][1][m][n]-inubin*x[j][k][l][m][n],0]+  
If[(l==5)&&(m==0)&&(n==0), inbin*Inh*x[j][k][3][m][n]-inubin*x[j][k][l][m][n],0]+  
If[(l==1)&&(m==1),-inbin*Nf*nInh*x[j][k][l][m][n]+  
inubin*x[j][k][4][m][n],0]+  
If[(l==3)&&(m==1),-inbin*Nf*nInh*x[j][k][l][m][n]+ inubin*x[j][k][5][m][n],0]+  





ar* If[m==1,Nf,1]*x[j][k][l][m][n]* Sum[x[0][kk][0][m][0],{kk,1,2}]+ dr*Sum[x[j][kk][l][m][n],{kk,1,2}],0]+
 If[(j==0)&&((k==1)||(k==2))&&(l==0)&&(n==0),-





















ac*If[m==1,Nf,1]*x[j][k][l][m][n]* Sum[x[0][0][ll][m][0],{ll,1,4,3}]+ dc*Sum[x[j][k][ll][m][n],{ll,1,4,3}],0]+ 
If[(j==0)&&(k==0)&&((l==1)||(l==4))&&(n==0),-










dc*x[j][k][l][m][n], 0]+  




 dc*x[j][k][l][m][n],0]+  




If[(j>2)&&(l==5)&&(n==0), ac*If[m==1,Nf,1]*x[j][k][2][m][n]*x[0][0][4][m][0]- dc*x[j][k][l][m][n],0]+  




If[(j>2)&&(l==3)&&(m==1)&&(n==1), ac*Nf*x[0][0][1][m][0]*x[j][k][2][m][n]-dc*x[j][k][l][m][n],0]+  




If[(j>2)&&(l==5)&&(m==1)&&(n==1), ac*Nf*x[0][0][4][m][0]*x[j][k][2][m][n]-dc*x[j][k][l][m][n], 0]  
PER-GSK3β 
x[j][k][l][m][n]'= 
If[(j>2)&&((l==0)||(l==1)),-If[m==1,Nf,1]*agp* x[j][k][l][m][n]*x[0][0][2][m][0]+dg*x[j][k][l+2][m][n],0]+  
If[(j>2)&&(l==4),-If[m==1,Nf,1]*agp*x[j][k][l][m][n]* x[0][0][2][m][0]+dg*x[j][k][5][m][n],0]+  
If[(j>2)&&((l==2)||(l==3)), If[m==1,Nf,1]*agp*x[j][k][l-2][m][n]*x[0][0][2][m][0]- dg*x[j][k][l][m][n],0]+  
If[(j>2)&&(l==5), If[m==1,Nf,1]*agp*x[j][k][4][m][n]*x[0][0][2][m][0]- dg*x[j][k][l][m][n],0]+  
If[(j==0)&&(k==0)&&(l==2)&&(n==0),-
If[m==1,Nf,1]*agp* Sum[x[jj][kk][ll][m][nn],{jj,3,6},{kk,0,2},{ll,{0,1,4}},{nn, 0,1}]*x[j][k][l][m][n]+ dg*Su
m[ x[jj][kk][ll][m][nn],{jj,3,6},{kk,0,2},{ll,{2,3,5}},{nn,0, 1}],0] 
PER-BMALs-CLOCK/NPAS2 
x[j][k][l][m][n]'= 
If[(j>0)&&(m==1)&&(n==0),-bbin*Nf*x[j][k][l][m][n]* x[0][0][0][m][1]+unbbin*x[j][k][l][m][1],0]+  
If[(j==0)&&(k==0)&&(n>0)&&(l==0)&&(m==1),-
bbin*Nf* x[0][0][0][m][n]* Sum[x[jj][kk][ll][m][0],{jj,1,6},{kk,0,2},{ll,0,5}]+ unbbin*Sum[x[jj][kk][ll][m][n]
,{jj,1,6},{kk,0,2},{ll,0,5}], 0]+ 



























CK1 inhibitor (PF-670462) 
x[j][k][l][m][n]'= 






















If[((j==1)||(j==3)||(j==5))&&(k==0),-If[(m==0)&&(n==1), 0,1]*upu*x[j][k][l][m][n],0]+  
If[((j==2))&&(k==0),-If[(m==0)&&(n==1),0,1]*up* x[j][k][l][m][n],0]+  





[jj][0][ll][m][nn],{jj,2,2},{nn,0,1},{ll,4,5}]+ upu*Sum[x[jj][0][ll][m][nn],{jj,1,5,2},{nn,0,1},{ll,4,5}], 0]+ 















11) Transcriptional Activity of GSK3β  
gto'=trgto*G*GB-ugto*gto 
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